Skip to main content

30-06-2021 | ADA 2021 | Conference coverage | News

News in brief

Semaglutide 2.4 mg reduces progression to type 2 diabetes

Alba Ruzafa

medwireNews: Taking semaglutide 2.4 mg can reduce the likelihood of people with overweight or obesity developing type 2 diabetes, shows further analysis of STEP 1.

Around 44% of the 1961 STEP 1 participants had prediabetes, with an average glycated hemoglobin of 5.9% (41 mmol/mol). During the 68-week trial, those taking semaglutide lost, on average, 13.7% of their baseline bodyweight, which was in line with the 14.9% reduction in the cohort overall.

Reporting the latest findings at the virtual ADA 81st Scientific Sessions, Leigh Perreault (University of Colorado Anschutz Medical Campus, Aurora, USA) revealed that 84.1% of the participants with prediabetes who were taking semaglutide reverted to normoglycemia, compared with 47.8% of those taking placebo.

A corresponding 15.3% versus 49.1% remained in the prediabetic range, and 0.5% versus 3.0% progressed to type 2 diabetes.

Among the people with baseline normoglycemia, 2.9% of those taking semaglutide progressed to prediabetes during the trial, but so did a significantly larger 10.9% of those taking placebo.

Reversion to normoglycemia was closely linked to the amount of weight lost, with rates in the semaglutide group ranging from 65.4% of those who lost less than 5% of their starting bodyweight to 95.3% of those who lost 20% or more. The pattern was the same in the placebo group, although the number of people with significant weight loss was much smaller; for example, three people lost 20% or more, compared with 142 people taking semaglutide.

medwireNews is an independent medical news service provided by Springer Healthcare Ltd. © 2021 Springer Healthcare Ltd, part of the Springer Nature Group

ADA Scientific Sessions; 25–29 June 2021

New additions to the Adis Journal Club

A selection of topical peer-reviewed articles from the Adis journals, curated by the editors.